Achieve better routine testing thanks to Cerba's broad portfolio

Routine safety analyses – alongside specialty testing – are widely considered the cornerstone of clinical trials. Cerba Research offers a diverse array of routine safety analyses, including hematology, serology, biochemistry and urinalysis evaluations.

Large medical laboratories are able to integrate Cerba Research’s clinical trial processes to deliver global analyses of all routine samples. Cerba Research’s assay analysis workflows are fully automated and high throughput, with all the company’s locations maintaining excess capacity.

Achieve better routine testing thanks to Cerba

Image Credit: Cerba Research

Standardization is ensured on a global scale, with all instruments regularly correlated via external proficiency tests to guarantee that comparable reference ranges are maintained.

Cerba Research leverages harmonized standard operating procedures (SOPs), uniform instruments and methods across all of its global laboratories. This approach ensures that results are comparable irrespective of location and that these results can be collated in a single central database.

The company employs a range of state-of-the-art instruments, including:

  • Roche Cobas®
  • Beckman Coulter
  • Sysmex
  • DiaSorin LIAISON®
  • Siemens ADVIA Centaur
  • Abbott ARCHITECT™

Accurate safety monitoring is a crucial step in the clinical development of any innovative therapy. Cerba Research’s advanced integration of routine and specialty testing via state-of-the-art technologies can help support this process.

About Cerba Research

For over 35 years, Cerba Research has been setting the industry standard for exemplary clinical trial conduct. Today, across five continents, with a focus on precision medicine, we are changing the paradigm of the central lab’s role in complex clinical research.

From protocol inception through development and to market, our passionate experts deliver the highest quality specialized and personalized laboratory and diagnostic solutions. Partner with us for the most efficient strategy to actualize your biotech and pharmaceutical products sooner and improve the lives of patients worldwide.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Apr 13, 2022 at 12:04 PM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cerba Research. (2022, April 13). Achieve better routine testing thanks to Cerba's broad portfolio. News-Medical. Retrieved on May 19, 2022 from https://www.news-medical.net/whitepaper/20220405/Achieve-better-routine-testing-thanks-to-Cerbas-broad-portfolio.aspx.

  • MLA

    Cerba Research. "Achieve better routine testing thanks to Cerba's broad portfolio". News-Medical. 19 May 2022. <https://www.news-medical.net/whitepaper/20220405/Achieve-better-routine-testing-thanks-to-Cerbas-broad-portfolio.aspx>.

  • Chicago

    Cerba Research. "Achieve better routine testing thanks to Cerba's broad portfolio". News-Medical. https://www.news-medical.net/whitepaper/20220405/Achieve-better-routine-testing-thanks-to-Cerbas-broad-portfolio.aspx. (accessed May 19, 2022).

  • Harvard

    Cerba Research. 2022. Achieve better routine testing thanks to Cerba's broad portfolio. News-Medical, viewed 19 May 2022, https://www.news-medical.net/whitepaper/20220405/Achieve-better-routine-testing-thanks-to-Cerbas-broad-portfolio.aspx.

Other White Papers by this Supplier